While facing cries that its cutting-edge hepatitis and HIV drugs are overpriced, Gilead Sciences Inc. awarded nearly $8 million in bonuses to its five top officers. John Martin, chairman and CEO of the Foster City-based company (NASDAQ: GILD) and the focus of much of the criticism, landed a bonus for 2013 of $3.5 million, the company said Wednesday in a Securities and Exchange Commission filing. Additionally, President and COO John Milligan scored a $1.5 million bonus for last year, Chief Scientific Officer Norbert Bischofberger won a nearly $1.1 million bonus, outgoing commercial operations chief Kevin Young got $978,000 and CFO Robin Washington received $787,500.
Help employers find you! Check out all the jobs and post your resume.
